Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.

This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.

This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.

In this study, patients with alopecia areata were found to have significantly lower serum vitamin D levels compared to those with vitiligo and healthy individuals, with lower levels correlating with increased disease severity.

This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

In this mouse study, severe selenoprotein deficiency in epidermal cells was linked to skin abnormalities, disrupted hair follicle development, and progressive alopecia, highlighting the role of selenoproteins in skin and hair health.

Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.

This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.

In this study, using topical crude onion juice significantly improved hair regrowth in patients with patchy alopecia areata compared to tap water.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This study concluded that cytokines and growth factors significantly regulate hair growth in vitro, with some completely inhibiting growth, such as EGF and TNFα.

This study found that individuals with androgenic alopecia have an increased number of thin hairs (less than 40 microns in diameter) per cm², which may affect their clinical appearance.

This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.

This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.

This review discusses androgenetic alopecia and alopecia areata through a systems biology lens, emphasizing the role of multi-omics data integration to explore molecular mechanisms and potential therapeutic strategies, but offers no new clinical results.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.